We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · December 27, 2020

Efficacy of Galcanezumab for Migraine Prevention in Patients With Anxiety and/or Depression

Headache

 

Additional Info

Disclosure statements are available on the authors' profiles:

Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
Headache 2020 Nov 01;60(10)2202-2219, TA Smitherman, GE Tietjen, K Schuh, V Skljarevski, S Lipsius, DN D'Souza, EM Pearlman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading